Eric L. Snyder, MD, PhD
Research and Clinical Interests
The molecular networks that specify cellular identity and suppress alternative cell fates are tightly regulated during normal tissue homeostasis. These networks are dysregulated during cancer progression, often with lethal consequences for cancer patients. Tumors with highly aberrant differentiation states typically exhibit a greater propensity for growth and metastasis than tumors which more closely resemble their tissue of origin.
Our laboratory seeks to decipher the master regulators that control cellular identity during cancer progression, with a particular focus on lung and pancreatic cancer. We have shown that loss of Nkx2-1/TTF1, a master regulator of lung development, leads to de-repression of a latent gastric differentiation program in lung adenocarcinoma. We are currently investigating mechanisms of this de-repression and its consequences for tumor growth. The long term goal of the lab is to determine how the loss of cellular identity and acquisition of alternative differentiation states contributes to cancer progression and alters therapeutic response.
- Snyder EL, Watanabe H, Magendantz M, Hoersch S, Chen TA, Wang DG, Crowley D, Whittaker CA, Kimura S, Meyerson M, Jacks T. Nkx2-1 represses a latent gastric differentiation program in lung adenocarcinoma. Molecular Cell 2013; 50: 185-199.
- Winslow MM, Dayton TD, Verhaak RGW, Snyder EL, Kim-Kiselak CS, Feldser DM, Whitaker CA, Hubbard DD, Crowley D, Bronson RT, Chiang DY, Meyerson M and Jacks T. Suppression of lung adenocarcinoma progression by Nkx2-1. Nature 2011; 473: 101-4.
- Snyder EL, Sandstrom DJ, Law K, Fiore C, Sicinska E, Brito J, Bailey D, Fletcher JA, Loda M, Rodig SJ, Cin PD, Fletcher CDM. c-Jun amplification and overexpression are oncogenic in liposarcoma but not always sufficient to inhibit the adipocytic differentiation program. J Pathol 2009; 218: 292-300.
- Snyder EL, Bailey D, Shipitsin M, Polyak K, Loda M. Identification of CD44v6+/CD24- breast carcinoma cells in primary human tumors by quantum dot-conjugated antibodies. Lab Invest 2009; 89: 857-866.
- Snyder EL*, Saenz CC*, Denicourt C, Meade BR, Cui X-S, Kaplan IM, Dowdy SF. Enhanced targeting and killing of tumor cells expressing the CXC chemokine receptor 4 by transducible anti-cancer peptides. Cancer Res 2005; 65:10646-50.
- Snyder EL, Meade BR, Saenz CC, Dowdy SF. Treatment of terminal peritoneal carcinomatosis by a transducible p53-activating peptide. PLoS Biol 2004; 2:186-193.
- 2011-present: Career Award for Medical Scientists, Burroughs Wellcome Fund
- 2011-present: Mentored Clinical Scientist Development Award (K08)
- 2014-2015: UCSF Program for Breakthrough Biomedical Research New Frontier Award
- Assistant Professor
- Cancer Research
- Phone: (415) 502-2887
- Fax: (415) 502-2888
- Eric L. Snyder, MD, PhD
- Pathology, Box 0452
- 513 Parnassus Avenue, Room S-1349B
- San Francisco, CA 94143
Other UCSF Organizational Association(s)
- Biomedical Sciences (BMS) Graduate Program
- UCSF Comprehensive Cancer Center